Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System

International Journal of Clinical Pharmacy · Published 2026-04-28 · DOI 10.1007/s11096-026-02153-9

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s11096-026-02153-9

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles